Will Tectonic Therapeutic announce topline results from the APEX trial of TX45 in pulmonary hypertension with heart failure with preserved ejection fraction by January 31, 2027?
deadline 2027-01-31
confidence medium
tier 4 evidence
78%Asturna estimate
⚠ Evidence cap applied: the model proposed 85%, brought back to 78% for lack of sources solid enough to justify the departure from the base rate.
Resolution criterion
Yes if, no later than January 31, 2027, Tectonic Therapeutic publicly reports the topline results of the APEX trial of TX45 (the outcome on the primary endpoint, positive or negative) in a press release or SEC filing. The deadline is the last day of the period the company gave in its filing ("January 2027"). An announcement of a delay or of a new timeline, enrollment or interim data that do not report the primary-endpoint outcome, or the absence of any announcement by that date, resolves NO.
Verified starting state
As of November 6, 2026: according to the Tectonic Therapeutic filing of November 5, 2026, the company expects topline results in the period "January 2027". Source: https://www.sec.gov/Archives/edgar/data/1681087/000119312526449965/tecx-ex99_1.htm
What pushes it up
- Tier‑1 SEC filing from Tectonic Therapeutic explicitly states topline results are expected in January 2027 [tier 1]
What pushes it down
- Typical clinical‑trial delays and the fact that the filing only announces an expectation, not a confirmed shipment of data; no actual results have been released yet [tier 1]
What would move this number most
Whether the trial proceeds on schedule and any unforeseen delays or regulatory issues that could postpone the announcement
How this number is built
| Deadline | 2027-01-31 |
| Base rate | 70% |
| Best evidence | tier 4 · 0 article(s) used |
| Independent runs | 63 · 78 · 78 (spread 15 pts) |
| Confidence | medium |
| Evidence cap | applied: 85% brought back to 78% |
| Last revised | 2026-11-06 21:54 |
| Model | openai/gpt-oss-20b (Groq) |